Some studies report a higher rate of return of menses after chemotherapy in patients who received a GnRH agonist (GnRH-a) compared to the controls [1-7]; however, there are data contradicting that thesis, asserting that the rates of ovarian insufficiency are similar [8-13]. Here, GNRH1 is linked to ovarian dysfunction.